Hôpitaux Universitaires Strasbourg - Hôpital de Hautepierre
- Address
- 1 Place De L Hopital, Cs 80426, 67091 STRASBOURG, Alsace, France
Oncology – Solid Tumors
At Hôpitaux Universitaires Strasbourg - Hôpital de Hautepierre the Medical Oncology department leads extensive research on a range of solid cancers, testing new systemic therapies and evaluating innovative treatment combinations to improve survival and quality of life.
- Advanced non‑small cell lung cancer
- Metastatic renal cell carcinoma
- Hepatocellular carcinoma
- Breast cancer (ER+/HER2‑)
- Colorectal and gastric cancers
- Sarcomas including osteosarcoma and Ewing sarcoma
The site supports 663 active trials with 19 investigators, focusing on novel immunotherapies, targeted agents and peri‑operative strategies.
Hematology – Leukemia and Lymphoma
Research in blood‑borne malignancies targets both acute and chronic diseases, aiming to refine transplant protocols and introduce antibody‑based treatments that can enhance remission rates.
- Acute myeloid leukemia
- Acute lymphoblastic leukemia
- Chronic lymphocytic leukemia
- Multiple myeloma
- Hodgkin and non‑Hodgkin lymphoma
Trials evaluate CAR‑T cells, bispecific antibodies and novel chemotherapy‑free regimens while monitoring long‑term graft‑versus‑host disease outcomes.
Immunology & Autoimmune Disorders
The department conducts studies on systemic immune diseases, testing biologics and steroid‑sparing approaches to reduce organ damage and improve patient‑reported outcomes.
- Systemic lupus erythematosus
- Rheumatoid arthritis
- ANCA‑associated vasculitis
- Idiopathic inflammatory myopathies
- Sjögren’s syndrome
- Inflammatory bowel disease
Innovative agents such as anti‑CD20, IL‑6 blockers and JAK inhibitors are under evaluation in well‑characterized patient cohorts.
Cardiovascular and Metabolic Research
Cardiovascular trials address acute events, chronic heart failure and metabolic risk factors, exploring new lipid‑lowering drugs, RAAS inhibitors and lifestyle‑integrated therapies.
- Acute coronary syndrome
- Chronic heart failure
- Atherosclerotic cardiovascular disease
- Hypertension and resistant hypertension
- Obesity and metabolic syndrome
- Metabolic dysfunction‑associated steatohepatitis (MASH)
Outcomes focus on mortality, hospitalisation rates and improvements in cardiac function or liver fibrosis.
Pulmonary and Infectious Disease Studies
Trials in respiratory medicine evaluate severe asthma, chronic obstructive pulmonary disease and emerging infectious threats, seeking therapies that reduce exacerbations and improve lung function.
- Severe eosinophilic asthma
- Chronic obstructive pulmonary disease
- COVID‑19 and post‑viral sequelae
- Nontuberculous mycobacterial lung infection
- Pulmonary hypertension
- Interstitial lung disease related to systemic sclerosis
Studies also incorporate advanced imaging and biomarker strategies to tailor treatment intensity.
Neurology and Neurodegeneration
Neurological research focuses on progressive disorders, evaluating disease‑modifying agents and precision diagnostics to slow cognitive decline and motor impairment.
- Early Alzheimer’s disease
- Parkinson’s disease
- Multiple sclerosis (relapsing and progressive forms)
- Diffuse intrinsic pontine glioma
- Epilepsy and focal onset seizures
Trials often combine immunotherapy with neuroprotective compounds and assess long‑term functional outcomes.
Pediatric Oncology and Rare Cancers
Children and adolescents are enrolled in trials targeting high‑risk solid tumours and rare malignancies, with an emphasis on reducing treatment toxicity while maintaining efficacy.
- High‑risk neuroblastoma
- Medulloblastoma
- Ewing sarcoma
- Wilms tumor
- Rare central nervous system tumors
- Advanced sarcomas with molecular alterations
Innovative approaches include metronomic chemotherapy, targeted inhibitors and early‑phase immunotherapies.
Diagnostic and Therapeutic Technologies
The site integrates cutting‑edge diagnostic tools and procedural innovations to enhance patient selection and treatment delivery across specialties.
- Contrast‑enhanced ultrasound for adnexal torsion
- Gadolinium‑based contrast safety in MRI
- Molecular profiling for targeted therapy allocation
- Minimally invasive surgical techniques
- Advanced anesthesia monitoring and analgesia
- Real‑time therapeutic drug monitoring
These technologies support personalized medicine initiatives and improve trial efficiency.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 36 therapeutic areas and 15 of 836 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 773 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 159 by active trials.
lock +158 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +103 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hôpitaux Universitaires Strasbourg - Hôpital de Hautepierre
lock Showing 1 of 699 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21181) A multicenter, randomized, prospective double-blind, cross over Phase 3 study to evaluate the efficacy and safety of 0.04 mmol Gd/kg body weight of gadoquatrane for MRI in adults with known or suspected pathology of the central nervous system (CNS), compared to 0.1 mmol Gd/kg approved macrocyclic gadolinium-based contrast agents (GBCAs) | Bayer AG | Phase III | Not Recruiting | Sep 2023 | Dec 2024 |
IMP list
lock Showing 1 of 836 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 42 | Unknown | 2010-03-18 | 2026-05-18 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.